De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

PDS Biotechnology Beheer

Beheer criteriumcontroles 2/4

De CEO PDS Biotechnology's is Frank Bedu-Addo, benoemd in Mar2019, heeft een ambtstermijn van 5.58 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 5.01M, bestaande uit 11.6% salaris en 88.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.88% van de aandelen van het bedrijf, ter waarde $ 2.64M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.3 jaar en 5.6 jaar.

Belangrijke informatie

Frank Bedu-Addo

Algemeen directeur

US$5.0m

Totale compensatie

Percentage CEO-salaris	11.6%
Dienstverband CEO	5.6yrs
Eigendom CEO	1.9%
Management gemiddelde ambtstermijn	2.3yrs
Gemiddelde ambtstermijn bestuur	5.6yrs

Recente managementupdates

Recent updates

PDS Biotechnology: Promising Phase 2 With Cash Issues That Might Be Worth The Risk

Jan 13

PDS Biotech announces preliminary efficacy readout from phase 2 combo trial of PDS0101

Feb 03

PDS Biotechnology gives new CFO ~202K stock grant

Jan 06

Analyse CEO-vergoeding

Hoe is Frank Bedu-Addo's beloning veranderd ten opzichte van PDS Biotechnology's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$41m
Mar 31 2024	n/a	n/a	-US$44m
Dec 31 2023	US$5m	US$580k	-US$43m
Sep 30 2023	n/a	n/a	-US$51m
Jun 30 2023	n/a	n/a	-US$48m
Mar 31 2023	n/a	n/a	-US$42m
Dec 31 2022	US$2m	US$540k	-US$41m
Sep 30 2022	n/a	n/a	-US$28m
Jun 30 2022	n/a	n/a	-US$28m
Mar 31 2022	n/a	n/a	-US$22m
Dec 31 2021	US$7m	US$475k	-US$17m
Sep 30 2021	n/a	n/a	-US$15m
Jun 30 2021	n/a	n/a	-US$12m
Mar 31 2021	n/a	n/a	-US$14m
Dec 31 2020	US$815k	US$450k	-US$15m
Sep 30 2020	n/a	n/a	-US$15m
Jun 30 2020	n/a	n/a	-US$17m
Mar 31 2020	n/a	n/a	-US$18m
Dec 31 2019	US$3m	US$356k	-US$7m

Compensatie versus markt: De totale vergoeding ($USD 5.01M ) Frank } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 677.23K ).

Compensatie versus inkomsten: De vergoeding van Frank is gestegen terwijl het bedrijf verliesgevend is.

CEO

Frank Bedu-Addo (59 yo)

5.6yrs

Tenure

US$5,011,234

Compensatie

Dr. Frank K. Bedu-Addo, Ph D., served as Interim Principal Financial Officer for PDS Biotechnology Corporation since September 30, 2021 until October 2021. Dr. Bedu-Addo was Chief Executive Officer of PDS...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Frank Bedu-Addo	President	5.6yrs	US$5.01m	1.88% $ 2.5m
Gregory Conn	Chief Scientific Officer	5.6yrs	US$1.68m	0.34% $ 440.0k
Lars Boesgaard	Principal Financial & Accounting Officer and CFO	less than a year	geen gegevens	geen gegevens
Stephan Toutain	Chief Operating Officer	less than a year	geen gegevens	geen gegevens
Joe Dervan	VP of Research & Development	3.8yrs	geen gegevens	geen gegevens
Deanne Randolph	Head of Investor Relations	no data	geen gegevens	geen gegevens
Spencer Brown	Senior VP	2.3yrs	geen gegevens	0% $ 0
Kirk Shepard	Chief Medical Officer	less than a year	geen gegevens	geen gegevens
Janetta Trochimiuk	Controller	no data	geen gegevens	geen gegevens

2.3yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van PDSB wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Frank Bedu-Addo	President	5.6yrs	US$5.01m	1.88% $ 2.5m
Gregory Freitag	Independent Director	5.6yrs	US$105.49k	0.13% $ 164.3k
Richard Sykes	Independent Director	5.6yrs	US$94.49k	1.21% $ 1.6m
Stephen Glover	Independent Chairman	5.5yrs	US$135.99k	0.17% $ 227.1k
Jerold Woodward	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Kamil Ali-Jackson	Independent Director	4.7yrs	US$106.49k	0.032% $ 41.9k
Mark Einstein	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Darron Brown	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Leaf Huang	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Samir Khleif	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Lisa Rohan	Chair of the Scientific Advisory Board	no data	geen gegevens	geen gegevens
Neil Gross	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens

5.6yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van PDSB wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.6 jaar).

PDS Biotechnology Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

PDS Biotechnology Corporation Appoints Stephan Toutain as Chief Operating Officer

PDS Biotechnology Corporation, Annual General Meeting, Jun 24, 2024

PDS Biotechnology Corporation Announces Executive Changes

Pds Biotech Announces CFO Changes

PDS Biotechnology Corporation, Annual General Meeting, Jul 14, 2023

Insufficient new directors

Recent updates

PDS Biotechnology Corporation Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation

PDS Biotechnology Corporation Announces Updated Results from VERSATILE-002 Phase 2 Clinical Trial Presented at ESMO 2024

New major risk - Revenue and earnings growth

PDS Biotechnology Corporation to Report Q2, 2024 Results on Aug 13, 2024

Pds Biotech Aligns with Fda on Phase 3 Trial in Hpv16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer

PDS Biotechnology Corporation(NasdaqCM:PDSB) dropped from Russell Small Cap Completeness Index

New minor risk - Market cap size

PDS Biotech Provides Data Update from Ongoing Versatile-002 Phase 2 Clinical Trial in Head and Neck Cancer

PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer

PDS Biotechnology Corporation to Report Q1, 2024 Results on May 15, 2024

PDS Biotechnology Corporation Appoints Stephan Toutain as Chief Operating Officer

PDS Biotechnology Corporation, Annual General Meeting, Jun 24, 2024

New minor risk - Market cap size

New minor risk - Shareholder dilution

PDS Biotechnology Corporation to Report Fiscal Year 2023 Results on Mar 27, 2024

PDS Biotechnology Corporation Announces Publication of Preclinical Research

PDS Biotechnology Corporation Announces Executive Changes

PDS Biotechnology: Promising Phase 2 With Cash Issues That Might Be Worth The Risk

Pds Biotech Announces CFO Changes

Price target decreased by 8.4% to US$17.67

PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of Pds0101-Based Triple Combination Therapy in Advanced Hpv16-Positive Cancer Patients

PDS Biotechnology Corporation to Report Q3, 2023 Results on Nov 14, 2023

PDS Biotechnology Corporation Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients At ESMO

PDS Biotechnology Corporation Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer

New major risk - Financial position

PDS Biotechnology Corporation Announces PDS0202 Elicits Active Neutralization of Multiple Influenza Strains in Preclinical Studies

PDS Biotech Announces Submission of Phase 3 Protocol to FDA to Initiate Versatile-003 Trial

PDS Biotechnology Corporation to Report Q2, 2023 Results on Aug 14, 2023

PDS Biotechnology Corporation to Present Updated Immune Response Data from Combination of PDS0101 and KEYTRUDA in Head and Neck Cancer Patients at ESMO Congress 2023

PDS Biotechnology Corporation Strengthens Intellectual Property Portfolio Governing A Combination of Versamune®? and PDS0301

PDS Biotechnology Announces Achievement of Efficacy Threshold in Stage 2 of the Versatile-002 Trial Evaluating Pds0101 and Keytruda in Head and Neck Cancer

PDS Biotechnology Corporation, Annual General Meeting, Jul 14, 2023

PDS Biotechnology Corporation Announces Interim Data Demonstrates 12-Month Survival Rate of 87% with PDS0101 in Combination with Keytruda (Pembrolizumab) for Head and Neck Cancer Patients

Pds Biotech Completes Enrollment in Immune Checkpoint Inhibitor Naïve Arm of Versatile-002 Phase 2 Clinical Trial in Advanced Hpv16 Positive Head and Neck Cancer

PDS Biotechnology Corporation to Report Q1, 2023 Results on May 15, 2023

Insufficient new directors

Price target increased by 7.9% to US$19.43

PDS Biotechnology Corporation Announces Preclinical Publication in Peer Reviewed Viruses Journal Showing Superior CD4 T Cell Induction by Infectimune

PDS Biotechnology Corporation Announces Preclinical Studies Involving Infectimune

PDS Biotechnology Corporation Announces Abstract Accepted for Presentation At ESMO Targeted Anticancer Therapies Congress

PDS Biotechnology Corporation Reports Median Overall Survival of 21 Months in Advanced, Refractory Cancer Patients Having Few Remaining Treatment Options and with Reported Historical Survival of 3-4 Months

Price target increased to US$18.25

PDS Biotech Completes First Stage of Enrollment in Checkpoint Inhibitor Refractory Arm of Phase 2 Clinical Trial in Advanced Hpv16 Positive Head and Neck Cancer

President exercised options and sold US$562k worth of stock

Price target increased to US$18.00

PDS Biotechnology Corporation Announces 100% Clinical Response in Cervical Cancer Patients in Preliminary Data from Immunocerv Phase 2 Clinical Trial

PDS Biotechnology Corporation Announces Presentation of Preliminary PDS0101 Efficacy, Safety, and Immunology Data at Society for Immunotherapy of Cancer (SITC 2022)

PDS Biotechnology Corporation to Report Q3, 2022 Results on Nov 14, 2022

PDS Biotech Announces Abstract Demonstrating Versatility of the Versamune® Platform in Oncology Accepted for Presentation at AACR Special Conference on Tumor Immunology and Immunotherapy

PDS Biotechnology Corporation Announces Expanded Interim Data in PDS0101 Triple Combination Phase 2 Trial Targeting Advanced HPV-Positive Cancers

Price target decreased to US$17.71

PDS Biotechnology Corporation Announces Successful End-of-Phase 2 Meeting With the FDA and Preparation for the Registrational Trial of PDS0101 in Combination With KEYTRUDA(R)

PDS Biotech jumps 13% as FDA clears further development of lead asset

PDS Biotechnology Corporation Biotech and National Cancer Institute Identify Optimal Patient Group for Advancing PDS0101-Based Triple Combination Program Targeting Advanced HPV-Positive Cancers

PDS Biotechnology files for $150 mixed shelf offering

PDS Biotech Independent Data Monitoring Committee Recommends Versatile-002 Trial Continuation Without Modifications

PDS Biotech spikes as panel backs continuation of cancer trial for lead asset

PDS Biotechnology Corporation to Report Q2, 2022 Results on Aug 08, 2022

PDS Biotechnology Corporation Announces Presentation of Universal Flu Vaccine Preclinical Data At American Society of Virology Meeting

PDS Biotechnology (NASDAQ:PDSB) Is In A Strong Position To Grow Its Business

PDS Biotechnology Corporation Appoints Spencer Brown as Senior Vice President, General Counsel

U.S. Food and Drug Administration Grants PDS Biotechnology Fast Track Designation for Lead Candidate Pds0101

PDS Biotechnology Corporation Announces Expansion of Its VERSATILE-002 Clinical Trial into Europe

PDS Biotechnology: Speculative Biotech Worth Buying After Latest Data

PDS Biotechnology Corporation Announces Presentation of Efficacy and Safety Data from VERSATILE-002 Phase 2 Clinical Trial in Recurrent or Metastatic Head and Neck Cancer At Asco 2022

PDS Biotechnology Corporation Appoints Sanjay Zaveri as Senior Vice President, Business Development

PDS Biotechnology Corporation, Annual General Meeting, Jun 15, 2022

PDS Biotech Announces Two Abstracts Accepted for Presentation at the 2022 American Society of Clinical Oncology Annual Meeting

Price target increased to US$20.50